Blog
RSS FeedPosted by Michael Wonder on 02 Sep 2019
Dutch experience demonstrates effective benchmarking of biosimilar use in health systems
31 August 2019 - As medicines become more numerous and often more expensive, health care professionals seek new ways to understand ...
Posted by Michael Wonder on 29 Aug 2019
EMA offers edits on FDA draft guidance on biosimilars
29 August 2019 - Although regulators rarely offer public comments on another regulator’s guidance, the European Medicines Agency (EMA) late ...
Posted by Michael Wonder on 27 Aug 2019
Congress should be promoting, not discouraging, the development of biosimilars
27 August 2019 - Drug prices continue to dominate the headlines, yet many of the policy ideas being considered in ...
Posted by Michael Wonder on 27 Aug 2019
We need a more rational biosimilars policy
27 August 2019 - Throwing in the towel on a whole new category of medicines, just shy of a decade in, ...
Posted by Michael Wonder on 26 Aug 2019
Don’t give up on biosimilars—Congress can give them a boost
25 August 2019 - Drugs grown in live cells are hard to replicate. But policy changes can help accelerate the process. ...
Posted by Michael Wonder on 22 Aug 2019
Time to throw in the towel on biosimilars
21 August 2019 - A major reason drugs are even mildly affordable in the U.S. is that cheap generic copies ...
Posted by Michael Wonder on 15 Aug 2019
UnitedHealthcare will prefer Amgen's anti-cancer biosimilars beginning in October
15 August 2019 - In its August 2019 network bulletin, UnitedHealthcare indicated that, beginning 1 October 2019, biosimilar bevacizumab (Mvasi) and ...
Posted by Michael Wonder on 08 Aug 2019
The economics of biologic drugs
8 August 2019 - The market for biologic drugs in the United States is large and growing. ...
Posted by Michael Wonder on 02 Aug 2019
Mylan and Biocon launch first trastuzumab biosimilar Ogivri in Australia
1 August 2019 - Biocon and Mylan today announced the launch in Australia of Ogivri (trastuzumab), a biosimilar to Herceptin ...
Posted by Michael Wonder on 24 Jul 2019
FDA approves Pfizer's biosimilar Ruxience (rituximab-pvvr), for certain cancers and auto-immune conditions
23 July 2019 - Pfizer today announced the United States FDA has approved Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab), ...
Posted by Michael Wonder on 24 Jul 2019
Merck's biosimilar to AbbVie's Humira wins FDA approval
24 July 2019 - The U.S. FDA approved Merck & Co Inc’s biosimilar to AbbVie's blockbuster rheumatoid arthritis treatment Humira, ...
Posted by Michael Wonder on 20 Jul 2019
Amgen and Allergan's Mvasi (bevacizumab-awwb) and Kanjinti (trastuzumab-anns) now available in the United States
19 July 2019 - First biosimilar Avastin and Herceptin products to launch in the United States. ...
Posted by Michael Wonder on 20 Jul 2019
Biosimilar drugs a boon to be applauded as they provide equivalent treatment at – sometimes – half the price
19 July 2019 - The fastest-growing segment of our health-care system is prescription drugs – now constituting the second-highest category ...
Posted by Michael Wonder on 20 Jul 2019
EU starts evaluating Samsung Bioepis’ sales application for Avastin biosimilar
19 July 2019 - Samsung Bioepis said that the EMA has started evaluating its application to market SB8, an Avastin ...
Posted by Michael Wonder on 17 Jul 2019
Part D beneficiaries may pay more for some generics, biosimilars than brand name drugs
16 July 2019 - Medicare Part D enrolees may actually pay more for some generic drugs than they would for their ...